Deprecated: Non-static method JSite::getMenu() should not be called statically, assuming $this from incompatible context in /eu.cbdna/public_html/templates/gk_shop_and_buy/lib/framework/helper.layout.php on line 148

Deprecated: Non-static method JApplication::getMenu() should not be called statically, assuming $this from incompatible context in /eu.cbdna/public_html/includes/application.php on line 536

915 Breast cancer and ovary cancer – analysis of mutation C5972T of BRCA2 gene

The test is appropriated for patients who have increased frequency of breast and ovary cancer occurrence in their families, and in particular:

- cancer occurrence at a young age, before the age of 50,

- ovary cancer, uterine tube cancer or peritoneum cancer,
- breast cancer of men

 

In Poland, in terms of genetic predisposition, the most frequently detected change is one of 5 mutations in BRCA1 gene or mutation C5972T of gene BRCA2. These types of mutations are inherited in an autosomal dominant way. The risk of developing neoplasm in carriers of mutation in BRCA2 is up to 80% in case of breast cancer and up to 35% in case of ovary cancer in the life cycle. Also the risk of developing other malignant neoplasm is increased. It is optimal to test one's carrier state of BRCA1 and BRCA2 mutations as early as possible in the adult life, with a view to implementing appropriate disease prophylaxis.

Test material: full blood (EDTA), cheek swab

Transfer method: blood: 4-10°C (a set for blood tests); cheek swab: room temperature (a set for cheek swabs)

Testing method: Direct sequencing of respective gene’s fragments

Delivery date: up to 10 business days